Velsera, formed by the merger of Seven Bridges, PierianDx, and UgenTec, has emerged as a global platform provider integrating multimodal data harmonization, clinical genomics interpretation, and IVD assay development for precision medicine. With operations across multiple continents, Velsera offers advanced analytic tools for biomarker discovery, workflow automation supporting regulatory compliance, and scalable solutions for next-generation sequencing interpretation. Their integrated approach bridges translational research with clinical implementation, accelerating targeted therapy development and adoption in oncology and genetic diagnostics.